[1] World Health Organization. WHO position papers on Haemophilus influenzae type b. 2022. https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/position-papers/haemophilus-influenzae-type-b. [2024-2-2].
[2] Ministry of Health of China, State Food and Drug Administration of China. National guideline for the surveillance of adverse events following immunization (AEFI). 2010. http://www.nhc.gov.cn/jkj/s3581/201402/5dd5633d93174a7c8e93d8af7579a613.shtml. [2023-1-10]. (In Chinese). 
[3] Ministry of Health of China. Identification of adverse reaction after immunization. 2018. http://www.nhc.gov.cn/fzs/s3576/201808/e4f7a5704a994a14bd28cd82f94d27e2.shtml. [2023-1-10]. (In Chinese). 
[4] Zhang LN, Li KL, Li Y, Fan CX, Li Y, Ren MR, et al. Surveillance of adverse events following immunization in China, 2020. Chin J Vaccines Immun 2022;28(2):208 − 18 https://doi.org/10.19914/j.CJVI.2022041. (in Chinese).
[5] Li ZQ, Xu JX, Tan HF, Zhang CH, Chen J, Ni LH, et al. Safety of pentavalent DTaP-IPV/Hib combination vaccine in post-marketing surveillance in Guangzhou, China, from 2011 to 2017. Int J Infect Dis 2020;99:149 − 55. https://doi.org/10.1016/j.ijid.2020.07.019CrossRef
[6] Dey A, Wang H, Quinn H, Pillsbury A, Hickie M, Deng L, et al. Surveillance of adverse events following immunisation in Australia annual report, 2020. Commun Dis Intell (2018) 2022;46:1-26. http://dx.doi.org/10.33321/cdi.2022.46.47.
[7] Pan XJ, Lv HK, Liang H, Wang Y, Shen LZ, Chen FX, et al. Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China. Hum Vaccin Immunother 2022;18(1):2021711. https://doi.org/10.1080/21645515.2021.2021711CrossRef
[8] Zhang LN, Li KL, Du W, Li Y, Fan CX, Yu WZ, et al. Surveillance of adverse events following immunization in China, 2019. Chin J Vaccines Immun 2021;27(4):438 − 45. https://doi.org/10.19914/j.CJVI.2021075. (in Chinese).
[9] Moro PL, Jankosky C, Menschik D, Lewis P, Duffy J, Stewart B, et al. Adverse events following Haemophilus influenzae type b vaccines in the vaccine adverse event reporting system, 1990-2013. J Pediatr 2015;166(4):992 − 7. https://doi.org/10.1016/j.jpeds.2014.12.014CrossRef
[10] Huang K, Tao S, Zhou XF, Mo JP, Zhu BW, Shen P, et al. Incidence rates of health outcomes of interest among Chinese children exposed to selected vaccines in Yinzhou Electronic Health Records: a population-based retrospective cohort study. Vaccine 2020;38(18):3422 − 8. https://doi.org/10.1016/j.vaccine.2020.03.013CrossRef
[11] Su JR, Moro PL, Ng CS, Lewis PW, Said MA, Cano MV. Anaphylaxis after vaccination reported to the vaccine adverse event reporting system, 1990-2016. J Allergy Clin Immunol 2019;143(4):1465 − 73. https://doi.org/10.1016/j.jaci.2018.12.1003CrossRef
[12] Bohlke K, Davis RL, Marcy SM, Braun MM, DeStefano F, Black SB, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003;112(4):815 − 20. https://doi.org/10.1542/peds.112.4.815CrossRef
[13] Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood 2014;124(22):3308 − 15. https://doi.org/10.1182/blood-2014-05-578336CrossRef
[14] Mossberg M, Segelmark M, Kahn R, Englund M, Mohammad AJ. Epidemiology of primary systemic vasculitis in children: a population-based study from southern Sweden. Scand J Rheumatol 2018;47(4):295 − 302. https://doi.org/10.1080/03009742.2017.1412497CrossRef
[15] Piram M, Maldini C, Biscardi S, De Suremain N, Orzechowski C, Georget E, et al. Incidence of IgA vasculitis in children estimated by four-source capture-recapture analysis: a population-based study. Rheumatology (Oxford) 2017;56(8):1358 − 66. https://doi.org/10.1093/rheumatology/kex158CrossRef